Omixon Signs Letter of Intent with Pronto Diagnostics

10/11/2014

At Omixon we are working hard to expand our customer base. Our Holotype HLA kit is already making an impact on the HLA typing market, and we are regularly contacted by companies proposing to partner with us as local distributors. For example, we have recently signed a letter of intent with Pronto Diagnostics and...

Omixon Celebrates a Frighteningly Successful ASHI 2014 in Denver

31/10/2014

Omixon took a team of scary mad scientists, zombie marketeers, and bloodsucking vampires (sales people) to Denver, Colorado, to the 40th Anniversary Meeting for the American Society of Histocompatibility and Immunogenetics (ASHI). Joining the team were a couple of respectable Omixon board members, who were neither undead nor scary (except...

SeqGene is Omixon’s New Distributor

15/10/2014

Omixon is pleased to announce the signature of a Distribution Agreement with SeqGene, based in Taipei City, Taiwan. The agreement is effective 1st October, 2014. About SeqGene: SeqGene is a molecular biology company. They specialize in next generation sequencing (NGS)-based services for oncology studies and HLA typing. The company is...

Join Us at ASHI for Free NGS Workshops on Holotype HLA™

08/10/2014

Novele Allele Discovery with HLA Twin genotyping software, featuring the Traffic Light System (TLS) for efficient throughput With 99.8% accuracy in genotyping NGS data, the Omixon Holotype HLA combined assay and software is the best way to Genotype. Contact us for more informations about our HLA Twin™ software. PresentersPeter Meintjes, PhD Peter has...

Omixon Collaborates with G3 and Genomics England to Validate HLA Genotyping from WGS Data

24/09/2014

Omixon has announced a collaboration with the Global Genomics Group (G3) to validate its Target HLA™ software to determine HLA genotypes from whole genome datasets. G3 is providing the whole genome datasets and the corresponding DNA samples of 340 subjects enrolled in the clinical trial called Genetic Loci and the...